To assess the efficacy of the huCD39 mAb in vivo, we evaluated the anti-tumor efficacy of targeting CD39 in human CD39 knock-in (KI) mice (purchased from Biocytogen) subcutaneously injected with MC38 tumor cells. This evidence concerns the gene ENTPD1 and neoplasm.